Caffeine

CHEMBL113 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

194.2 g/mol

LogP

-0.1

Phase

4

A widely consumed methylxanthine stimulant that blocks adenosine receptors in the brain, promoting wakefulness and alertness. Medically, it is used in combination with analgesics for headaches, as a respiratory stimulant in premature infants, and is being studied for neuroprotective effects in conditions like Parkinson's disease. Excessive intake can cause anxiety, insomnia, and elevated heart rate.

Berat Molekul

194,1900 g/mol

LogP

-0,10

TPSA

58,40 Å²

Lipinski RO5

Lulus

Area Terapeutik

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Benign Prostatic Hyperplasia Glaucoma Cardiovascular Disease Age-Related Macular Degeneration Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Obesity Transplant Medicine Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis Chronic Pain Malaria HIV/AIDS Hepatitis C Tuberculosis Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cn1c(=O)c2c(ncn2C)n(C)c1=O

InChI

InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3

Molecular Formula

C8H10N4O2

HBD / HBA

- / 3

Ikatan yang Dapat Dirotasi

0

Atom Berat

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A widely consumed methylxanthine stimulant that blocks adenosine receptors in the brain, promoting wakefulness and alertness. Medically, it is used in combination with analgesics for headaches, as a respiratory stimulant in premature infants, and is being studied for neuroprotective effects in conditions like Parkinson's disease. Excessive intake can cause anxiety, insomnia, and elevated heart rate.

Yes, Caffeine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL113. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2519. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Caffeine di PillFYI

Struktur

Data Cepat

Rumus: C8H10N4O2
Sinonim: 265

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.